US6184225B1
(en)
|
1996-02-13 |
2001-02-06 |
Zeneca Limited |
Quinazoline derivatives as VEGF inhibitors
|
DE69709319T2
(en)
|
1996-03-05 |
2002-08-14 |
Astrazeneca Ab |
4-ANILINOQUINAZOLINE DERIVATIVES
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
US6258820B1
(en)
|
1999-03-19 |
2001-07-10 |
Parker Hughes Institute |
Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
|
US6126917A
(en)
*
|
1999-06-01 |
2000-10-03 |
Hadasit Medical Research Services And Development Ltd. |
Epidermal growth factor receptor binding compounds for positron emission tomography
|
KR100849151B1
(en)
|
1999-11-05 |
2008-07-30 |
아스트라제네카 아베 |
Quinazoline derivatives as vegf inhibitors
|
BR0112355A
(en)
*
|
2000-06-26 |
2005-04-19 |
Univ Michigan |
Use of egf-r tyrosine kinase protein inhibitors for the prevention of human skin photoaging
|
WO2002036587A2
(en)
|
2000-11-01 |
2002-05-10 |
Cor Therapeutics, Inc. |
Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
|
CA2994779C
(en)
|
2001-02-19 |
2020-08-25 |
Novartis Ag |
Use of 40-o-(2-hydroxyethyl)-rapamycin for inhibiting growth of a solid tumour of the brain other than lymphatic cancer
|
BR0209647A
(en)
|
2001-05-16 |
2004-07-27 |
Novartis Ag |
A combination comprising n- {5- [4- (4-methyl-piperazine-methyl) -benzoylamido] -2-methyl-phenyl} -4- (3-pyridyl) -2-pyrimidine-amine and a chemotherapeutic agent
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
PL372103A1
(en)
|
2002-05-16 |
2005-07-11 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
CL2004001120A1
(en)
|
2003-05-19 |
2005-04-15 |
Irm Llc |
COMPOUNDS DERIVED FROM AMINA REPLACED WITH HETEROCICLES, IMMUNOSUPPRESSORS; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT DISEASES MEDIATED BY LYMPHOCYTE INTERACTIONS, SUCH AS AUTOIMMUNE, INFLAMMATORY, INFECTIOUS, CANCER DISEASES.
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
AU2005231956B2
(en)
|
2004-04-07 |
2009-11-05 |
Novartis Ag |
Inhibitors of IAP
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
AU2006204052A1
(en)
*
|
2005-01-03 |
2006-07-13 |
Cytovia, Inc. |
Method of treating brain cancer
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
GB0519879D0
(en)
|
2005-09-30 |
2005-11-09 |
Astrazeneca Ab |
Chemical process
|
PT2275103E
(en)
|
2005-11-21 |
2014-07-24 |
Novartis Ag |
Mtor inhibitors in the treatment of endocrine tumors
|
AU2007218725B2
(en)
|
2006-02-21 |
2011-12-01 |
Eisai R & D Management Co., Ltd. |
4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
US20090098137A1
(en)
|
2006-04-05 |
2009-04-16 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
EP2606890A1
(en)
|
2006-04-05 |
2013-06-26 |
Novartis AG |
Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
|
CN101443002B
(en)
|
2006-05-09 |
2012-03-21 |
诺瓦提斯公司 |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
CA2664378A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
EP2120900A2
(en)
|
2007-02-15 |
2009-11-25 |
Novartis AG |
Combination of lbh589 with other therapeutic agents for treating cancer
|
CA2678477A1
(en)
|
2007-02-16 |
2008-08-21 |
Eisai R&D Management Co., Ltd. |
Crystal, amorphous form and salt of methyl n-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
|
KR20100042245A
(en)
|
2007-08-17 |
2010-04-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Method for producing quinazoline derivative
|
EP2202229B1
(en)
*
|
2007-08-17 |
2012-03-14 |
Eisai R&D Management Co., Ltd. |
Novel preparation for external use
|
KR101673621B1
(en)
|
2008-03-24 |
2016-11-07 |
노파르티스 아게 |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
EP2628726A1
(en)
|
2008-03-26 |
2013-08-21 |
Novartis AG |
Hydroxamate-based inhibitors of deacetylases b
|
ES2704986T3
(en)
|
2008-10-16 |
2019-03-21 |
Celator Pharmaceuticals Inc |
Combinations of a water-soluble liposomal camptothecin with cetuximab or bevacizumab
|
UY32330A
(en)
|
2008-12-18 |
2010-07-30 |
Novartis Ag |
NEW FORM OF SALT OF ACID 1- (4- {1- [E-4-CICLOHEXIL-3-TRIFLUORO-METIL-BENCILOXI-IMINO] -ETIL} -2-ETIL-BENCIL) -AZETIDIN-3-CARBOXYLICAL, POLYMODIC FORMS , PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
|
CN103204794A
(en)
|
2008-12-18 |
2013-07-17 |
诺瓦提斯公司 |
New Salts
|
RU2011129230A
(en)
|
2008-12-18 |
2013-01-27 |
Новартис Аг |
NEW POLYMORPHIC FORM 1- [4- [1- (4-Cyclohexyl-3-trifluoromethylbenzyloxylimino) Ethyl] -2-Ethylbenzyl] Azetidine-3-Carboxylic Acid
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
UA105794C2
(en)
|
2009-06-26 |
2014-06-25 |
Новартіс Аг |
1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS Cyp17 INHIBITORS
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
AU2010283806A1
(en)
|
2009-08-12 |
2012-03-01 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
MX2012002066A
(en)
|
2009-08-17 |
2012-03-29 |
Intellikine Inc |
Heterocyclic compounds and uses thereof.
|
JP5775871B2
(en)
|
2009-08-20 |
2015-09-09 |
ノバルティス アーゲー |
Heterocyclic oxime compounds
|
EP2470502A1
(en)
|
2009-08-26 |
2012-07-04 |
Novartis AG |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
IN2012DN02139A
(en)
|
2009-09-10 |
2015-08-07 |
Novartis Ag |
|
AU2010317167B2
(en)
|
2009-11-04 |
2012-11-29 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful as MEK inhibitors
|
JP6220126B2
(en)
|
2009-11-23 |
2017-10-25 |
セルリアン・ファーマ・インコーポレイテッド |
Polymers based on cyclodextrins for therapeutic delivery
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
EP2509964B1
(en)
|
2009-12-08 |
2014-04-30 |
Novartis AG |
Heterocyclic sulfonamide derivatives
|
CU24130B1
(en)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
ISOQUINOLINONES AND REPLACED QUINAZOLINONES
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
EP2582680A1
(en)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
JP2013532149A
(en)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
Piperidinyl-substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives
|
UA112517C2
(en)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
BR112013015449A2
(en)
|
2010-12-21 |
2016-09-20 |
Novartis Ag |
biheteroaryl compounds as vps23 inhibitors
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
JP5808826B2
(en)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
Heterocyclic compounds and uses thereof
|
WO2012120469A1
(en)
|
2011-03-08 |
2012-09-13 |
Novartis Ag |
Fluorophenyl bicyclic heteroaryl compounds
|
KR20140025492A
(en)
|
2011-04-28 |
2014-03-04 |
노파르티스 아게 |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
EA201391820A1
(en)
|
2011-06-09 |
2014-12-30 |
Новартис Аг |
HETEROCYCLIC SULPHONAMIDE DERIVATIVES
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
EA201490164A1
(en)
|
2011-06-27 |
2014-04-30 |
Новартис Аг |
SOLID FORMS AND SALTS DERIVATIVES OF TETRAHYDROPYRIDOPYRIMIDINE
|
WO2013038362A1
(en)
|
2011-09-15 |
2013-03-21 |
Novartis Ag |
6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
SI2794600T1
(en)
|
2011-12-22 |
2018-03-30 |
Novartis Ag |
2,3-Dihydro-benzo(1,4)oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
WO2013096051A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
CA2859869A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
AU2012355624A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
BR112014015274A8
(en)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compounds and compositions for inhibiting bcl2 interaction with binding partners
|
BR112014015308A2
(en)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compounds for inhibiting bcl2 interaction with binding counterparts
|
UY34591A
(en)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
IMIDAZOPIRROLIDINONA COMPOUNDS
|
CN104245701A
(en)
|
2012-04-03 |
2014-12-24 |
诺华有限公司 |
Combination products with tyrosine kinase inhibitors and their use
|
US9365576B2
(en)
|
2012-05-24 |
2016-06-14 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
WO2013188763A1
(en)
|
2012-06-15 |
2013-12-19 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
US9738643B2
(en)
|
2012-08-06 |
2017-08-22 |
Duke University |
Substituted indazoles for targeting Hsp90
|
WO2014071402A1
(en)
|
2012-11-05 |
2014-05-08 |
Dana-Farber Cancer Institute, Inc. |
Xbp1, cd138, and cs1, pharmaceutical compositions that include the peptides, and methods of using such petides and compositions
|
TW201422625A
(en)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
Solid form of dihydro-pyrido-oxazine derivative
|
EP2948451B1
(en)
|
2013-01-22 |
2017-07-12 |
Novartis AG |
Substituted purinone compounds
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
EP3626741A1
(en)
|
2013-02-20 |
2020-03-25 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
CN105246482A
(en)
|
2013-03-15 |
2016-01-13 |
因特利凯有限责任公司 |
Combination of kinase inhibitors and uses thereof
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(en)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
RU2675105C9
(en)
|
2013-09-22 |
2019-01-09 |
Саншайн Лейк Фарма Ко., Лтд. |
Substituted aminopyrimidine compounds and methods of use
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
WO2015148714A1
(en)
|
2014-03-25 |
2015-10-01 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
US9394281B2
(en)
|
2014-03-28 |
2016-07-19 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
AU2015241198A1
(en)
|
2014-04-03 |
2016-11-17 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
JP6526789B2
(en)
|
2014-07-31 |
2019-06-05 |
ノバルティス アーゲー |
Combination therapy
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
US11261187B2
(en)
|
2016-04-22 |
2022-03-01 |
Duke University |
Compounds and methods for targeting HSP90
|
US20190209669A1
(en)
|
2016-08-23 |
2019-07-11 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
CA3035080A1
(en)
|
2016-09-27 |
2018-04-05 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
CA3073421A1
(en)
|
2017-09-26 |
2019-04-04 |
Daniel Mark COREY |
Chimeric engulfment receptor molecules and methods of use
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and hdac inhibitors for treating multiple myeloma
|
JP2021500409A
(en)
|
2017-10-24 |
2021-01-07 |
オンコペップ, インコーポレイテッド |
Peptide vaccines and pembrolizumab for treating breast cancer
|
JP7254076B2
(en)
|
2017-11-19 |
2023-04-07 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
Substituted heteroaryl compounds and methods of use
|
EP3730483B1
(en)
|
2017-12-21 |
2023-08-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
CA3093969A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
WO2019191334A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
RU2020135107A
(en)
|
2018-03-28 |
2022-04-29 |
Серо Терапьютикс, Инк. |
CELLULAR IMMUNOTHERAPEUTIC COMPOSITIONS AND THEIR APPLICATIONS
|
EP3826988A4
(en)
|
2018-07-24 |
2023-03-22 |
Hygia Pharmaceuticals, LLC |
Compounds, derivatives, and analogs for cancer
|
EP4038097A1
(en)
|
2019-10-03 |
2022-08-10 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
JP2023536346A
(en)
|
2020-08-05 |
2023-08-24 |
エリプシーズ ファーマ リミテッド |
Treatment of Cancer with Cyclodextrin-Containing Polymeric Topoisomerase Inhibitor Conjugates and PARP Inhibitors
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
TW202237638A
(en)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
|
IL305411A
(en)
|
2021-02-26 |
2023-10-01 |
Kelonia Therapeutics Inc |
Lymphocyte targeted lentiviral vectors
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2023240105A1
(en)
*
|
2022-06-07 |
2023-12-14 |
Biomimetix Jv, Llc |
Hydrophobic compositions including a hydrophilic active ingredient and methods relating thereto
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|